The South Australian immunoGENomics Cancer Institute (SAiGENCI) will employ a collaborative approach to cancer research and care.
It will bring together clinicians, clinical and biomedical researchers, state and federal decision makers and the community.
CALHN and SAiGENCI
The Central Adelaide Local Health Network (CALHN) plays an important role in improving the health and wellbeing of South Australians. It delivers world-class integrated healthcare, and general and quaternary hospital services.
CALHN has a strong commitment to the delivery of clinical services in an environment that is supportive of, and informed by, research across all disciplines.
CALHN’s involvement as an alliance partner in SAiGENCI is fundamental to the new institute’s approach to building strong collaborative links between clinical and research communities. This partnership will lead to improved treatment and care options for South Australians living with cancer.
The University of Adelaide and SAiGENCI
The University of Adelaide is consistently ranked in the top 1% of universities globally and is South Australia’s only Group of Eight research intensive university.
One hundred percent of the University’s research is rated 'world standard or above', with med-tech and health included as one of its primary research strengths.
With these credentials, the University of Adelaide is well placed to host SAiGENCI, and it has made a strong commitment to the collaborative creation of an ecosystem that will attract and retain the brightest minds in cancer research. Boosting the cancer research capability in South Australia.
It’s the University’s mission to take an international leadership role in cancer research and innovation, and to support continuous improvements in health care delivery for those who battle cancer.